The full results of a dementia drug trial usually show up in four places. The first is the trial's record on ClinicalTrials.gov. The second is the peer-reviewed journal paper. The third is the FDA's review documents and drug label, once the drug is approved. The fourth is an independent evidence review. A press release is the company's summary, and those four sources hold the numbers that summary is based on.
Each source answers a different question. The registry shows what the trial set out to measure. The journal paper gives the full effect sizes and side effects. The FDA files show what regulators accepted. Independent reviews weigh how much the benefit matters. You can check all four yourself for free.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Official resources:
- View the official study record on ClinicalTrials.gov — Use this record to verify the study status and eligibility details.
- View the official study record on ClinicalTrials.gov — Use this record to verify the study status and eligibility details.
Table of Contents
- Why the Press Release Comes Out Before the Full Data
- How to Read a Trial Record on ClinicalTrials.gov
- What the Journal Paper Shows That a Headline Leaves Out
- Does the Result Apply to Your Family Member?
- Where the FDA's Own Analysis Lives
- Independent Reviews for a Second Opinion
- Frequently Asked Questions
Why the Press Release Comes Out Before the Full Data
Companies often announce "topline" results within weeks of a trial ending. Topline results are a short list of the main findings. The detailed data follows on a slower, legally set schedule. ClinicalTrials.gov's reporting requirements say sponsors of most Phase 2–4 trials of FDA-regulated drugs generally must post summary results within 12 months of the trial's primary completion date. That deadline can stretch.
According to ClinicalTrials.gov's explanation of FDAAA 801 and the Final Rule, a sponsor seeking FDA approval can file a certification that generally delays posting for up to two years. A promising announcement and a blank results tab can sit side by side for a long time. The rules don't only cover drug companies. NIH-funded trials must register and report results on ClinicalTrials.gov whether or not the FDA regulates the product. That means academic dementia studies are covered too.
How to Read a Trial Record on ClinicalTrials.gov
Search the drug name or the trial's nickname, which press releases usually mention (for example, "Clarity AD"). Open the record and check these parts: If the deadline has passed with nothing posted, the record may carry a "Late Results – per FDAAA" flag.
The UCSF Office of Ethics and Compliance notes that sponsors who miss the deadline can face civil money penalties. The flag itself tells you the full data are still missing.
- **Primary outcome measure:** the main result the trial was designed to test. If the press release leads with something else, note that.
- **Eligibility criteria:** who could join, including disease stage and any required biomarker tests.
- **Enrollment and dates:** how many people took part and when the primary completion date fell.
- **Results tab:** summary tables of outcomes and adverse events, once posted.
What the Journal Paper Shows That a Headline Leaves Out
Lecanemab, an Alzheimer's drug, is a good example. It was widely reported as slowing decline by 27%. The peer-reviewed Clarity AD paper in the New England Journal of Medicine turns that percentage into actual points. People on the drug declined 1.21 points on the 18-point CDR-SB scale over 18 months. People on placebo declined 1.66 points. The difference was about 0.45 points across 1,795 people with early Alzheimer's. The CDR-SB (Clinical Dementia Rating–Sum of Boxes) scores memory, orientation, judgment, community affairs, home life and personal care.
A higher score means more impairment. A relative percentage sounds big. The raw gap on the scale is what tells you how much daily function changed. The same paper gives the harms in detail. The NEJM Clarity AD publication reported brain swelling, called ARIA-E, in 12.6% of people on lecanemab versus 1.7% on placebo. Microbleeds or bleeding, called ARIA-H, occurred in 17.3% versus 9.0%. Short announcements often summarize these numbers loosely.
Does the Result Apply to Your Family Member?
Trial results only apply to people like those who were enrolled. Clarity AD enrolled people with mild cognitive impairment or mild dementia who had confirmed amyloid, a protein that builds up in the brain in Alzheimer's.
Its findings don't cover moderate or advanced dementia. Before bringing a new drug up with a doctor, compare the trial's eligibility list with the person's situation:.
- Diagnosis stage: mild cognitive impairment, mild, moderate or advanced dementia.
- Whether amyloid has been confirmed by a scan or spinal fluid test.
- The type of dementia. An Alzheimer's trial says nothing about vascular or Lewy body dementia.
Where the FDA's Own Analysis Lives
After approval, Drugs@FDA posts approval letters, labels and the FDA's review documents. The reviews contain the agency's own analysis of the trial data. The FDA's Drugs@FDA overview notes that most of these documents are available for drugs approved since 1998.
For a faster route, the FDALabel database searches the text of more than 160,000 labeling documents. Open a label's "Clinical Studies" section for the effect sizes the FDA accepted. Then read "Warnings and Precautions" for the risks, including any monitoring requirements.
Independent Reviews for a Second Opinion
Independent groups publish their own assessments of dementia drug evidence. The Institute for Clinical and Economic Review (ICER) published a lecanemab report on April 17, 2023. You can read it next to the company's claims and the journal paper.
These reviews are useful when the benefit is small and the risks need monitoring. That's the situation where a family has to weigh trade-offs. Bring the specific numbers, such as the point difference and the ARIA rates, to the prescribing neurologist and ask how they apply to this patient.
Frequently Asked Questions
What does "topline results" mean in a press release?
It's the sponsor's short first summary of a trial's main findings, released before the full data tables and peer-reviewed paper.
Why would a trial's results tab still be empty a year after it ended?
A sponsor seeking FDA approval can generally delay posting results for up to two years by filing a certification.
Is a 27% slowing the same as a 27% improvement?
No. It means decline was smaller than on placebo. In Clarity AD, that came to about 0.45 points on an 18-point scale over 18 months, and patients still declined.
Do these reporting rules cover university-led studies?
Yes, if NIH funds them. NIH-funded trials must register and report results on ClinicalTrials.gov even when the FDA doesn't regulate the product.
